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Prostate cancer is a common malignancy in men, with a markedly variable clinical course.
Somatic alterations in DNA drive the growth of prostate cancers and may underlie the
behavior of aggressive versus indolent tumors. The accelerating application of genomic
technologies over the last two decades has identiﬁed mutations that drive prostate cancer
formation, progression, and therapeutic resistance. Here, we discuss exemplary somatic
mutations in prostate cancer, and highlight mutated cellular pathways with biological and
possible therapeutic importance. Examples include mutated genes involved in androgen
signaling, cell cycle regulation, signal transduction, and development. Some genetic alter-
ations may also predict the clinical course of disease or response to therapy, although the
molecular heterogeneity of prostate tumors poses challenges to genomic biomarker iden-
tiﬁcation. The widespread application of massively parallel sequencing technology to the
analysis of prostate cancer genomes should continue to advance both discovery-oriented
and diagnostic avenues.
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Prostate cancer is the second most common cancer in men world-
wide and causes over 250,000 deaths each year (Jemal etal.,2011).
However, many men with prostate cancer do not develop symp-
tomatic disease. Overtreatment of indolent tumors may result in
signiﬁcant morbidity. A deeper understanding of the genomic
differences between lethal and indolent prostate cancer, as well
as elucidation of “druggable” effectors dysregulated by genetic
alterations, should improve patient stratiﬁcation and speed the
development of targeted therapies.
Withtheadvanceofgenomecharacterizationtechnologiesover
thelasttwodecades,thesomaticalterationsthatmaydriveprostate
tumors have come into sharper focus. In this mini-review,we sur-
veytheﬁeldofprostatecancergenomics,highlightrecentﬁndings,
and discuss prospects for future research.
THE MUTATIONAL SPECTRUM OF PROSTATE CANCER
All categories of DNA sequence alterations contribute to prostate
tumorigenesis, including point mutations, small insertions or
deletions, copy number changes, and chromosomal rearrange-
ments (Figure 1). An overview of each category of alteration, and
its contribution to prostate cancer biology, is presented below.
SOMATIC COPY NUMBER ALTERATION
Most prostate cancers exhibit somatic copy number alterations
(SCNAs), with genomic deletions outnumbering ampliﬁcations
in early stages of disease (Visakorpi etal., 1995). Early stud-
ies relied on cytogenetics, ﬂuorescence in situ hybridization and
molecular genetic approaches to map candidate cancer genes to
r egio nso fSCN A(Brothmanetal.,1999). Inrecentyears,compar-
ative genomic hybridization and high-density single nucleotide
polymorphism arrays have allowed high-resolution genome-wide
analysis of SCNAs. Statistical analyses of genome-wide copy
number data have narrowed the boundaries of recurrent alter-
ations considerably and have pinpointed novel cancer genes in
these regions (Beroukhim etal., 2007; Taylor etal., 2010; Robbins
etal.,2011).
The extent of SCNA is generally modest in pre-cancerous pro-
static intraepithelial neoplasia (PIN), but becomes increasingly
prevalent along the spectrum from localized adenocarcinoma to
metastatic disease (Zitzelsberger etal., 2001). Particular recurrent
SCNAs are enriched in advanced tumors. For example, tumors
that fail androgen ablation therapy show frequent ampliﬁcation
of chromosomes 7, 8q and X (Visakorpi etal., 1995; Alers etal.,
2000; Holcomb etal., 2009). Animal models of prostate cancer
indicate that genes in these regions,such as the androgen receptor
gene (X) and the MYC proto-oncogene (8q),contribute to cancer
progression (discussed in detail below).
POINT MUTATIONS AND SMALL INSERTIONS–DELETIONS
Relativetostructuralalterations,recurrentpointmutationsareless
common in primary prostate cancers (Kan etal., 2010). Primary
tumors generally harbor one to two somatic variants per million
base pairs – far fewer than known carcinogen-driven tumors such
as lung cancer or melanoma, but comparable to breast, renal, or
ovarian cancers (Greenman etal., 2007; Pleasance etal., 2010a,b;
Berger etal.,2011). While most of these mutations confer no pro-
liferative advantage, a handful of recurrent oncogenic mutations
have been deﬁned.
The reported prevalence of mutations in several known cancer
genes varies widely and depends on tumor purity, stage, histo-
logical grade, and exposure to treatments. For example, RB1,
TP53, and PTEN are preferentially mutated in locally advanced
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FIGURE 1 | Genomic alterations in four high-risk prostate cancers.
Circos plots depicting genomic rearrangements and copy number
alterations in four prostate tumors analyzed by whole-genome sequencing
(unpublished data). Green and pink lines designate intrachromosomal and
interchromosomal rearrangements, respectively. Somatic copy number
alterations are indicated in red (ampliﬁcation) and blue (deletion) in the inner
rings. Gleason scores indicate the two most prevalent histologic grades in
each tumor. Pathological stage is noted as well, where pT3 indicates locally
invasive disease.
or metastatic tumors (Eastham etal., 1995; Tricoli etal., 1996;
Cairns etal., 1997) while the androgen receptor is mutated only
in metastatic or treatment-resistant disease (Linja and Visakorpi,
2004;Tayloretal.,2010).Ethnicitymayinﬂuencemutationpreva-
lence as well. Activating mutations in KRAS and BRAF occur in
∼10% of Asian patients but are rare in Caucasian men, perhaps
reﬂecting different environmental etiology or biological behavior
of cancers in these populations (Watanabe etal., 1994; Konishi
etal.,1997; Cho etal., 2006).
DefectsinDNAmismatchrepair(MMR)machineryhavebeen
reported in prostate cancers and may accelerate progression to
castration-independence (Dahiya etal., 1997; Chen etal., 2001).
Large-scale sequencing studies have recently identiﬁed a subset of
tumors with markedly elevated rates of point mutation (Taylor
etal.,2010;Kumaretal.,2011;unpublisheddata). Itremainstobe
determinedwhetherthehighlevelsofmutationinthesetumorsare
caused by MMR deﬁciency, and whether hyper-mutated cancers
display more clinically aggressive behavior.
STRUCTURAL REARRANGEMENTS
The discovery of ETS family gene fusions in roughly half of
prostate cancers heralded a novel class of alterations in epithelial
malignancies as a whole (Tomlins etal.,2005). The most common
and prototypical ETS fusion places the oncogenic ERG transcrip-
tion factor under control of the androgen-regulated TMPRSS2
gene,leadingtohighexpressionintheprostateepithelium. Subse-
quent research has identiﬁed a host of similar oncogenic fusions,
where a proto-oncogene is adjoined to a highly active promoter
(Tomlins etal., 2007; Kumar-Sinha etal., 2008; Palanisamy etal.,
2010). Since mutation or ampliﬁcation of oncogenes is less com-
mon in early-stage prostate cancer, genomic rearrangements may




cer. Primary tumors may harbor an average of approximately
100 rearrangements, including translocations, deletions, inser-
tions,and inversions (Figure.1; Berger etal.,2011). Some tumors
display “closed chains” of balanced rearrangements, in which
multipleDNAbreaksoccurthroughoutthegenomeandtheresult-
ing fragments are shufﬂed and rejoined to one another. These
rearrangements may arise when the affected genetic loci are phys-
ically proximal to each other, possibly due to co-regulation by
transcriptional machinery or nuclear co-localization in open- or
closed-chromatin compartments (Osborne etal., 2004; Berger
etal., 2011). Consistent with this hypothesis, androgen stimula-
tion can induce physical co-localization of TMPRSS2 and ERG
and permit fusion of these genes de novo via a topoisomerase
2B-mediated mechanism (Haffner etal., 2010).
The diverse categories of genomic aberrations underscore the
need for comprehensive genomic analyses both to understand
tumor biology and to direct targeted therapies on a genotype-
speciﬁc basis (Roychowdhury etal., 2011).
CELLULAR PATHWAYS DYSREGULATED BY RECURRENT
PROSTATE CANCER GENOMIC ALTERATIONS
Genomic alterations in prostate cancer can increasingly be con-
ceptualized in terms of the molecular processes and pathways on
which they impinge (Taylor etal., 2010). Mutations in prostate
cancer may affect signal transduction pathways that regulate
growth and proliferation, as well as genes involved in the nor-
mal development of the prostate. Below, we highlight several
themesandpathwaysthatprovideaframeworkforunderstanding
genomic alterations in prostate cancer.
PI3K AND MAPK SIGNALING
The phosphoinositide 3-kinase (PI3K) pathway is a central medi-
ator of cellular proliferation and growth that is aberrantly acti-
vated in prostate cancer. In response to pro-proliferative signals,
PI3K catalyzes the formation of phosphatidylinositol (3,4,5)-
triphosphate (PIP3),which recruitsAkt to the plasma membrane.
Uponphospho-activationattheplasmamembrane,Aktphospho-
rylates a wide array of substrates that promote proliferation and
cell survival.
Prostate tumors achieve activation of PI3K signaling most
frequently via inactivation of the tumor-suppressor gene PTEN
(Figure2). PTEN encodes a lipid–protein phosphatase that coun-
teracts signaling by PI3K via dephosphorylation of PIP3. Loss of
heterozygosity at the PTEN locus is found in up to 70% of pri-
mary prostate cancers and inactivating mutations occur in 5–10%
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FIGURE 2 | Somatic alterations in the PI3K pathway in prostate cancer.
Selected genes in the PI3K pathway are depicted, alongside the mechanisms
by which they are altered in prostate cancer. Putative proto-oncogenes are
boxed in red and tumor-suppressor genes in blue. PI3K signaling is frequently
activated by deletion of PTEN. PHLPP1 encodes a phosphatase that
dephosphorylates activated Akt, and is frequently co-deleted with PTEN in
metastatic tumors (Chen etal., 2011). Genomic rearrangements disrupt
MAGI2, which encodes a scaffolding protein that stabilizes PTEN (Wu etal.,
2000; Berger etal., 2011). Recurrent deletions inactivate the FOXO1A gene,
which encodes a transcription factor substrate of Akt that mediates PI3K
signaling. Although rare, oncogenic mutations in the receptor tyrosine kinase
EGFR or AKT1 may activate the pathway upstream or downstream of PI3K
(Cai etal., 2008; Boormans etal., 2010).The expression of most pathway
members is dysregulated at the transcript level as well.
(Cairns etal., 1997; Gray etal., 1998; Barbieri etal., 2012). Inac-
tivation of PTEN is enriched in advanced tumors and correlates
with decreased cancer-speciﬁc survival (McMenamin etal., 1999;
Sircar etal., 2009). PTEN loss in the mouse prostate collaborates
withothertumor-promotingeventssuchaslossofTP53andover-
expression of c-Myc or ERG (Chen etal., 2005; King etal., 2009;
Kim etal., 2012).
Ampliﬁcation of PIK3CA, which encodes the catalytic sub-
unit of PI3K, occurs in 13–39% of primary tumors and
50% of castration-resistant tumors (Edwards etal., 2003; Sun
etal., 2009; Agell etal., 2011). Activating mutations have been
observed in ∼5% of primary tumors (Sun etal., 2009; Bar-
bieri etal., 2012). PIK3CA activation and PTEN loss tend to
be mutually exclusive, which suggests functional redundancy
– although larger sample sizes are needed to assess this rela-
tionship robustly (Sun etal., 2009). Interestingly, PTEN loss
and PIK3CA activation co-occur in endometrial cancer, suggest-
ing that multiple lesions are required to activate the pathway,
or that these events engage disparate oncogenic mechanisms
(Oda etal., 2005). In support of the latter possibility, onco-
genic Akt-independent signaling downstream of mutant PIK3CA
has been observed in both primary tumors and cancer cell lines
(Vasudevan etal., 2009).
The PI3K pathway may be activated by genomic alterations
at additional pathway nodes and dysregulated expression of con-
stituent genes (Figure 2; Dong etal., 2006; Cai etal., 2008; Taylor
etal.,2010). Determining whether these lesions predict sensitivity
orresistancetoPI3Kpathwayinhibitorshasbecomeanactivearea
of translational research.
The mitogen-activated protein kinase (MAPK) pathway also
playsaroleinprostatecancerpathogenesis,especiallyinadvanced
andcastration-resistanttumors.MAPKpathwayactivationisasso-
ciated with higher tumor stage and grade and recurrent disease
(Gioelietal.,1999).Inthesettingofcastrationresistance,PI3Kand
MAPK signaling are often coordinately dysregulated (Gao etal.,
2006; Kinkade etal., 2008). Evidence for collaboration between
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these pathways continues to emerge. For instance,PTEN-induced
senescencemaybeovercomebyup-regulationof MAPKsignaling
induced by overexpression of HER2 (Ahmad etal., 2011).
Up-regulation of RAS family members, RAF1 and BRAF,o r
down-regulation of SPRY1 or SPRY2 genes, are common and
enriched in prostate cancer metastases (Kwabi-Addo etal., 2004;
McKie etal., 2005; Taylor etal., 2010). In some cases, expression
of RAS, RAF1, and BRAF is activated by oncogenic fusions with
highly expressed promoters (Palanisamy etal., 2010; Wang etal.,
2011). Repression of the RAS-GAP gene DAB2IP by EZH2 may
activate MAPK signaling and drive progression and metastasis
(Min etal., 2010). Deﬁning the relevant mechanisms of pathway
activationingreaterdetailwilllikelyinformstrategiesfortargeting
castration-resistant tumors.
CELL CYCLE REGULATORY GENES
Several cell cycle regulatory genes are disrupted in prostate can-
cer. Inactivation of cell cycle inhibitors appears to be required
to avoid senescence induced by oncogenic signaling and pos-
sibly to bypass androgen-regulation of growth in metastatic or
castration-resistant tumors.
Twocriticalcellcycleregulatorygenes,TP53andRB1,arecom-
monly deleted or mutated in metastatic tumors (Bookstein etal.,
1993; Heidenberg etal., 1995; Tricoli etal., 1996; Hyytinen etal.,
1999). p53 activates expression of the p21WAF1 cyclin-dependent
kinase inhibitor, and the Rb protein regulates transition from
the G1 to S cell cycle phase. RB1 inactivation is common in
castration-resistant tumors (Holcomb etal., 2009; Sharma etal.,
2010). Likewise, inactivation of p53 is necessary to bypass cellu-
lar senescence mechanisms that are activated upon loss of PTEN
(Chen etal., 2005).
Another key cell cycle regulator,CDKN1B,encodes the p27Kip1
cyclin-dependent kinase inhibitor, and resides within the 12p13
chromosomal region that is frequently deleted. Low p27Kip1
expression correlates with poor pathological prognostic mark-
ers (Vis etal., 2000; Dreher etal., 2004). Ampliﬁcation of SKP2,
which encodes a ubiquitin ligase that targets p27Kip1 for protea-
somal degradation, may also serve to inactivate p27Kip1 (Taylor
etal., 2010; Robbins etal., 2011). Disruption of CDKN1B pro-
motes prostate cancer coordinately with hemizygous deletion
of PTEN, suggesting an interaction between p27Kip1 and the
PI3K pathway (Di Cristofano etal., 2001). Likewise, p27Kip1
induces senescence in PIN lesions driven by Akt1 in mice
(Majumder etal., 2008).
DEVELOPMENTAL AND ANDROGEN-REGULATED GENES
Normal developmental and androgen-regulated processes appear
to be co-opted during oncogenesis in the prostate. Several genes
that participate in the development and differentiation of the
prostate epithelium are dysregulated in prostate cancer (Prins and
Putz, 2008).
The androgen receptor regulates cellular proliferation and
differentiation in response to hormonal signals in the prostate
epithelium. While androgen receptor is not mutated in pri-
mary tumors, the AR gene is frequently mutated or ampliﬁed
in metastatic and castration-resistant disease (Visakorpi etal.,
1995; Koivisto etal., 1997; Linja and Visakorpi, 2004). AR point
mutationsallowpromiscuousactivationbysteroidhormonessuch
as estrogens, progestins, glucocorticoids, and androgen antago-
nists in 10–30% of refractory cases (Gaddipati etal., 1994; Linja
andVisakorpi,2004).Alterationofandrogensignalingmaypartic-
ipate in localized disease as well: several AR-interacting genes are
mutated or dysregulated in primary tumors, including NCOR2,
NRIP1,TNK2, and EP300 (Taylor etal.,2010).
NKX3-1 encodes a prostate-speciﬁc transcription factor that is
required for normal development of the prostate and is deleted or
down-regulated in up to 90% of prostate cancers (Emmert-Buck
etal., 1995; Vocke etal., 1996; Asatiani etal., 2005). Inactiva-
tion via hemizygous deletion of chromosome 8p appears to
occur early and can be observed in PIN lesions (Emmert-Buck
etal., 1995; Asatiani etal., 2005). NKX3-1-deﬁcient mice exhibit
defective branching morphogenesis of the prostate gland and
develop PIN-like lesions with age (Bhatia-Gaur etal., 1999). In
addition, NKX3-1 appears to protect the differentiated prostate
epithelium from oxidative DNA damage (Ouyang etal., 2005;
Bowen and Gelmann, 2010). Therefore, loss of NKX3-1 may
both disrupt terminal differentiation and foster the muta-
tional inactivation of collaborating cancer genes such as PTEN
(Kim etal., 2002).
The Wnt pathway regulates embryological development, and
its contribution to prostate cancer is becoming increasingly rec-
ognized (Yardy and Brewster,2005). Key pathway genes including
APC,AXIN1 and the β-catenin gene CTNNB1 may be mutated at
low frequency (Voeller etal.,1998; Chesire etal.,2000;Yardy etal.,
2009). APC undergoes LOH in roughly 20% of primary cancers
andpromoterCpGmethylationinupto90%(Brewsteretal.,1994;
Phillips etal., 1994; Yegnasubramanian etal., 2004). β-Catenin
may promote proliferation through co-activation of AR-mediated
transcription (Truica etal., 2000; Cronauer etal., 2005). Addi-
tionalmutationsinWntpathwaygeneswererecentlydocumented
in the progression to castration-resistant disease (Kumar etal.,
2011). More pairs of pre- and post-relapse samples should be
analyzed to clarify the importance of this pathway in refractory
disease.
GENOMIC HETEROGENEITY OF PROSTATE CANCER
Prostate cancer is a clinically and genetically heterogeneous dis-
ease. Independent cancerous foci with distinct morphological
features often coexist in a single prostate. The course of dis-
ease also varies widely: some cancers remain indolent for decades
while others rapidly progress to lethality. Distinct molecular fea-
tures appear to underlie the clinical and histological differences.
Identifying genomic determinants of aggressive disease might
improveexperimentalmodelingandstratiﬁcationof patientswith
intermediate-risk prostate cancer.
Prostate cancer may arise in multiple foci from independent
precursor cells that are driven to neoplastic transformation by
carcinogenic exposures or genetic predisposition (Andreoiu and
Cheng, 2010). The presence of genomic lesions can vary between
foci, including TMPRSS2-ERG fusion, MYC ampliﬁcation, and
TP53 mutation (Mirchandani etal., 1995; Jenkins etal., 1997;
Mehra etal., 2007). Multiple distinct clones can be identiﬁed in
a single biopsy (Ruiz etal., 2011), but most metastatic prostate
cancers appear to originate from a single clone within a primary
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tumor (Qian etal., 1995; Holcomb etal., 2009; Liu etal., 2009).
Amongotherlesions,subclonalTP53mutationsmaydeﬁnecellsin
the primary tumor with metastatic potential (Mirchandani etal.,
1995;Navoneetal.,1999).Intratumoralheterogeneitycomplicates
efforts to deﬁne prognostic mutations or expression signatures
from primary tumors, because the subclone within a primary
tumor that gives rise to metastatic disease must be adequately
sampled (Sboner etal., 2010).
Despite the challenges posed by tumor heterogeneity, expres-
sion signatures have been proposed that delineate histologically
aggressive disease or predict outcome independently of clinical
variables (Singh etal., 2002; Glinsky etal., 2004; True etal., 2006;
Febbo,2009).However,theoverlapbetweensignaturesfrominde-
pendent studies is moderate. Some genomic alterations appear to
have prognostic value as well. The TMPRSS2-ERG fusion, MYC
ampliﬁcation,and PTEN or TP53 deletion predict cancer-speciﬁc
deathinatleastsomepatientcohorts(Satoetal.,1999;Demichelis
etal., 2007; Sircar etal., 2009). In some cases, a mutational signa-
ture may underlie expression-based sub-classiﬁcations (Lapointe
etal.,2004,2007).
PROSTATE CANCER IN THE ERA OF GENOMICS-DRIVEN
MEDICINE
High-throughputgenomicproﬁlinghasadvancedtheunderstand-
ing, prognostication, and treatment of several tumor types. For
example, identiﬁcation of mutations in BAP1 in uveal melanoma
(Harbour etal.,2010)o rIDH1 in glioblastoma and acute myeloid
leukemia (Parsons etal., 2008; Mardis etal., 2009) demonstrated
the power of genome sequencing to pinpoint novel cancer-
drivingmutations. Risk-predictivetranscriptionalsignatureshave
improved prognostication for patients with breast cancer (van ’t
Veer etal., 2002), while the mutational status of EGFR in non-
small cell lung cancer predicts clinical response to inhibitors of
thiskinase(Paezetal.,2004).Prostatecancermaybesimilarlyripe
for discovery of novel cancer genes and biomarkers as well, since
genomiccharacterizationoflargecohortsofaggressivetumorshas
only recently become feasible.
Indeed,whole-exome sequencing of over 100 primary prostate
tumor–normal pairs revealed that the ubiquitin ligase complex
subunit gene SPOP is among the most frequently mutated genes
inprimarytumors,thoughitsroleincancerwasheretoforeunrec-
ognized (Barbieri etal., 2012). This study also identiﬁed novel
recurrent mutations in the fork-head transcription factor gene
FOXA1 and mediator complex gene MED12. Experimental study
will be required to determine whether these mutations engage
known molecular pathways relevant to prostate cancer or reﬂect
novel mechanisms of oncogenesis.
Severalhurdlesmustbeovercomeforprostatecancergenomics
to impact the clinical management of this disease. For instance,
biopsies produce scarce material for clinical genotyping and may
not fully capture the relevant molecular heterogeneity within a
tumor. Expressionsignatureshavenotyetdemonstratedsufﬁcient
prognostic value to merit widespread use. In addition, recur-
rent genomic lesions identiﬁed thus far are largely not considered
“druggable.”
These challenges can likely be surmounted by new approaches.
For example, genomic characterization may identify opportuni-
ties to leverage synthetic lethality by inhibiting targets that are
essential in the setting of a particular mutation, such as poly
(ADP-ribose) polymerase in ETS-fusion positive prostate cancer
(Brenner etal., 2011). The analysis of multiple samples from a
primary tumor and perhaps from circulating tumor cells may
allow aggressive tumor subclones to be identiﬁed. Ultimately,new
paradigmsforclinicaltrialsmayberequiredthatincorporatecan-
cer genomic information. In spite of these challenges, genomic
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